Coya Therapeutics Inc COYA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting
Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Trading Information
- Previous Close Price
- $2.81
- Day Range
- $2.74–2.76
- 52-Week Range
- $2.74–6.53
- Bid/Ask
- $2.75 / $2.88
- Shares Outstanding
- 23.46M
- Market Cap
- $66.39M
- Volume/Avg
- 5,361 / 143,289
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.97
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 8
Valuation
Metric | COYA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.52 |
Price/Sales | 6.97 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | COYA |
|---|---|
Quick Ratio | 12.29 |
Current Ratio | 13.40 |
Interest Coverage | — |
Quick Ratio
COYA
Profitability
Metric | COYA |
|---|---|
Return on Assets (Normalized) | −37.86% |
Return on Equity (Normalized) | −42.85% |
Return on Invested Capital (Normalized) | −42.85% |
Return on Assets
COYA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|v<fbf% | LOCK|&$m# | $138B | |||
| Moderna Inc MRNA | LOCK|KK?GVC | LOCK|k$ | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|!t$GR? | LOCK|M^<^j | $93B | |||
| argenx SE ADR ARGX | LOCK|vqXDw$X | LOCK|WGh | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|T>j%Yv | LOCK|m<d | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|tfgs@Tg | LOCK|Dq?J< | $30B | |||
| Incyte Corp INCY | LOCK|^jJM<Y | LOCK|!z | $24B | |||
| BioNTech SE ADR BNTX | LOCK|n&$h<N | LOCK|F?x | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|@>SB^sN | LOCK|<^$PB | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|@c%!C^ | LOCK|q&v | $15B |
United States